Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nutrition & Metabolism
Published in: Nutrition & Metabolism 1/2017

Open Access 01-12-2017 | Review

Phosphatidic acid: biosynthesis, pharmacokinetics, mechanisms of action and effect on strength and body composition in resistance-trained individuals

Author: Peter Bond

Published in: Nutrition & Metabolism | Issue 1/2017

Login to get access

Abstract

The mechanistic target of rapamycin complex 1 (mTORC1) has received much attention in the field of exercise physiology as a master regulator of skeletal muscle hypertrophy. The multiprotein complex is regulated by various signals such as growth factors, energy status, amino acids and mechanical stimuli. Importantly, the glycerophospholipid phosphatidic acid (PA) appears to play an important role in mTORC1 activation by mechanical stimulation. PA has been shown to modulate mTOR activity by direct binding to its FKBP12-rapamycin binding domain. Additionally, it has been suggested that exogenous PA activates mTORC1 via extracellular conversion to lysophosphatidic acid and subsequent binding to endothelial differentiation gene receptors on the cell surface. Recent trials have therefore evaluated the effects of PA supplementation in resistance-trained individuals on strength and body composition. As research in this field is rapidly evolving, this review attempts to provide a comprehensive overview of its biosynthesis, pharmacokinetics, mechanisms of action and effect on strength and body composition in resistance-trained individuals.
Literature
1.
Karagounis LG, Hawley JA. Skeletal muscle: increasing the size of the locomotor cell. Int J Biochem Cell Biol. 2010;42(9):1376–9.CrossRefPubMed
2.
Tesch P. Skeletal muscle adaptations consequent to long-term heavy resistance exercise. Med Sci Sports Exerc. 1988;20(5 Suppl):132–4.CrossRef
3.
Churchward-Venne TA, Burd NA, Phillips SM. Nutritional regulation of muscle protein synthesis with resistance exercise: strategies to enhance anabolism. Nutr Metab. 2012;9(1):1.CrossRef
4.
Buford TW, Kreider RB, Stout JR, Greenwood M, Campbell B, Spano M, Ziegenfuss T, Lopez H, Landis J, Antonio J. International society of sports nutrition position stand: creatine supplementation and exercise. J Int Soc Sports Nutr. 2007;4(1):1.CrossRef
5.
Bond P. Regulation of mtorc1 by growth factors, energy status, amino acids and mechanical stimuli at a glance. J Int Soc Sports Nutr. 2016;13(1):1.CrossRef
6.
7.
Huang K, Fingar DC. Growing knowledge of the mtor signaling network. Semin Cell Dev Biol. 2014;36:79–90.CrossRefPubMed
8.
9.
Ma XM, Blenis J. Molecular mechanisms of mtor-mediated translational control. Nat Rev Mol Cell Biol. 2009;10(5):307–18.CrossRefPubMed
10.
Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein s6 kinase (s6k) within mtor signalling networks. Biochem J. 2012;441(1):1–21.CrossRefPubMed
11.
12.
Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. Pras40 is an insulin-regulated inhibitor of the mtorc1 protein kinase. Mol Cell. 2007;25(6):903–15.CrossRefPubMed
13.
Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, Lin HC, Yancopoulos GD, Glass DJ. Insulin-like growth factor-1 (igf-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin (pi3k/akt/mtor) pathway. J Biol Chem. 2005;280(4):2737–44.CrossRefPubMed
14.
Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P, Byfield MP, Backer JM, Natt F, Bos JL, et al. Amino acids mediate mtor/raptor signaling through activation of class 3 phosphatidylinositol 3oh-kinase. Proc Natl Acad Sci U S A. 2005;102(40):14238–43.CrossRefPubMedPubMedCentral
15.
Hornberger TA, Stuppard R, Conley KE, Fedele MJ, Fiorotto ML, ESSER KA, et al. Mechanical stimuli regulate rapamycin-sensitive signalling by a phosphoinositide 3-kinase-, protein kinase b-and growth factor-independent mechanism. Biochem J. 2004;380(3):795–804.CrossRefPubMedPubMedCentral
16.
Inoki K, Zhu T, Guan K-L. Tsc2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577–90.CrossRefPubMed
17.
O’Neil TK, Duffy L, Frey J, Hornberger T. The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions. J Physiol. 2009;587(14):3691–701.CrossRefPubMedPubMedCentral
18.
Yoon M-S, Son K, Arauz E, Han JM, Kim S, Chen J. Leucyl-trna synthetase activates vps34 in amino acid-sensing mtorc1 signaling. Cell Rep. 2016;16(6):1510–7.CrossRefPubMedPubMedCentral
19.
Castro-Gomez P, Garcia-Serrano A, Visioli F, Fontecha J. Relevance of dietary glycerophospholipids and sphingolipids to human health. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA). 2015;101:41–51.CrossRef
20.
Yoon M-S, Rosenberger CL, Wu C, Truong N, Sweedler JV, Chen J. Rapid mitogenic regulation of the mtorc1 inhibitor, deptor, by phosphatidic acid. Mol Cell. 2015;58(3):549–56.CrossRefPubMedPubMedCentral
21.
Joy JM, Gundermann DM, Lowery RP, J¨ager R, McCleary SA, Purpura M, Roberts MD, Wilson SM, Hornberger TA, Wilson JM. Phosphatidic acid enhances mtor signaling and resistance exercise induced hypertrophy. Nutr Metab. 2014;11:1.CrossRef
22.
Hoffman JR, Stout JR, Williams DR, Wells AJ, Fragala MS, Mangine GT, Gonzalez AM, Emerson NS, McCormack WP, Scanlon TC, et al. Efficacy of phosphatidic acid ingestion on lean body mass, muscle thickness and strength gains in resistance-trained men. J Int Soc Sports Nutr. 2012;9(1):1.CrossRef
23.
Escalante G, Alencar M, Haddock B, Harvey P. The effects of phosphatidic acid supplementation on strength, body composition, muscular endurance, power, agility, and vertical jump in resistance trained men. J Int Soc Sports Nutr. 2016;13(1):1.CrossRef
24.
Andre TL, Gann JJ, McKinley-Barnard SK, Song JJ, Willoughby DS. Eight weeks of phosphatidic acid supplementation in conjunction with resistance training does not differentially affect body composition and muscle strength in resistance-trained men. J Sports Sci Med. 2016;15:532–9.PubMedPubMedCentral
25.
Gonzalez AM, Sell KM, Ghigiarelli JJ, Kelly CF, Shone EW, Accetta MR, Baum JB, Mangine GT. Effects of phosphatidic acid supplementation on muscle thickness and strength in resistance-trained men. Applied Physiology, Nutrition, and Metabolism (ja). 2017. doi:10.​1139/​apnm-2016-0564.
26.
Athenstaedt K, Daum G. Phosphatidic acid, a key intermediate in lipid metabolism. Eur J Biochem. 1999;266(1):1–16.CrossRefPubMed
27.
28.
Lagace TA, Ridgway ND. The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2013;1833(11):2499–510.CrossRef
29.
Tang W, Yuan J, Chen X, Gu X, Luo K, Li J, Wan B, Wang Y, Yu L. Identification of a novel human lysophosphatidic acid acyltransferase, lpaat-theta, which activates mtor pathway. BMB Rep. 2006;39(5):626–35.CrossRef
30.
Biao L, Jiang YJ, Yaling Z, HATCH GM, et al. Cloning and characterization of murine 1-acyl-sn-glycerol 3-phosphate acyltransferases and their regulation by pparα in murine heart. Biochem J. 2005;385(2):469–77.CrossRef
31.
Zhang C, Wendel AA, Keogh MR, Harris TE, Chen J, Coleman RA. Glycerolipid signals alter mtor complex 2 (mtorc2) to diminish insulin signaling. Proc Natl Acad Sci. 2012;109(5):1667–72.CrossRefPubMedPubMedCentral
32.
Hornberger T, Chu W, Mak Y, Hsiung J, Huang S, Chien S. The role of phospholipase d and phosphatidic acid in the mechanical activation of mtor signaling in skeletal muscle. Proc Natl Acad Sci U S A. 2006;103(12):4741–6.CrossRefPubMedPubMedCentral
33.
You J-S, Lincoln HC, Kim C-R, Frey JW, Goodman CA, Zhong X-P, Hornberger TA. The role of diacylglycerol kinase ζ and phosphatidic acid in the mechanical activation of mammalian target of rapamycin (mtor) signaling and skeletal muscle hypertrophy. J Biol Chem. 2014;289(3):1551–63.CrossRefPubMed
34.
Su W, Yeku O, Olepu S, Genna A, Park J-S, Ren H, Du G, Gelb MH, Morris AJ, Frohman MA. 5-fluoro-2-indolyl des-chlorohalopemide (fipi), a phospholipase d pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol. 2009;75(3):437–46.CrossRefPubMed
35.
36.
Foster DA, Salloum D, Menon D, Frias MA. Phospholipase d and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin (mtor). J Biol Chem. 2014;289(33):22583–8.CrossRefPubMedPubMedCentral
37.
Bobrovnikova-Marjon E, Pytel D, Riese MJ, Vaites LP, Singh N, Koretzky GA, Witze EE, Diehl JA. Perk utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate akt activation and promote adipocyte differentiation. Mol Cell Biol. 2012;32:2268–78. doi:10.​1128/​MCB.​00063-12.CrossRefPubMedPubMedCentral
38.
M’erida I, Avila-Flores A, Merino E. Diacylglycerol kinases: at the hub of cell signalling. Biochem J. 2008;409:1–18.CrossRef
39.
Avila-Flores A, Santos T, Rinc’on E, M’erida I. Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. J Biol Chem. 2005;280(11):10091–9.CrossRefPubMed
40.
41.
Gibellini F, Smith TK. The kennedy pathway—de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB life. 2010;62(6):414–28.CrossRefPubMed
42.
Vance JE, Tasseva G. Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2013;1831(3):543–54.
43.
Viaud J, Mansour R, Antkowiak A, Mujalli A, Valet C, Chicanne G, Xuereb J-M, Terrisse A-D, S’everin S, Gratacap M-P, et al. Phosphoinositides: important lipids in the coordination of cell dynamics. Biochimie. 2016;125:250–8.CrossRefPubMed
44.
45.
Morita S-Y, Terada T. Enzymatic measurement of phosphatidylglycerol and cardiolipin in cultured cells and mitochondria. Sc Rep. 2015;5:11737.CrossRef
46.
Tanaka T, Kassai A, Ohmoto M, Morito K, Kashiwada Y, Takaishi Y, Urikura M, Morishige J-I, Satouchi K, Tokumura A. Quantification of phosphatidic acid in foodstuffs using a thin-layer-chromatography-imaging technique. J Agric Food Chem. 2012;60(16):4156–61.CrossRefPubMed
47.
Van den Bosch H, Postema N, De Haas G, Van Deenen L. On the positional specificity of phospholipase a from pancreas. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid. Metabolism. 1965;98(3):657–9.
48.
Purpura M, J¨ager R, Joy JM, Lowery RP, Moore JD, Wilson JM. Effect of oral administration of soy-derived phosphatidic acid on concentrations of phosphatidic acid and lyso-phosphatidic acid molecular species in human plasma. J Int Soc Sports Nutr. 2012;10(1):22.
49.
Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mtor signaling. Science. 2001;294(5548):1942–5.CrossRefPubMed
50.
Winter JN, Fox TE, Kester M, Jefferson LS, Kimball SR. Phosphatidic acid mediates activation of mtorc1 through the erk signaling pathway. Am J Phys Cell Phys. 2010;299(2):335–44.CrossRef
51.
Veverka V, Crabbe T, Bird I, Lennie G, Muskett F, Taylor R, Carr M. Structural characterization of the interaction of mtor with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the frb domain in small molecule-mediated regulation of mtor. Oncogene. 2008;27(5):585–95.CrossRefPubMed
52.
Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, Jiang Y. Rheb activates mtor by antagonizing its endogenous inhibitor, fkbp38. Science. 2007;318(5852):977–80.CrossRefPubMed
53.
Yoon M-S, Sun Y, Arauz E, Jiang Y, Chen J. Phosphatidic acid activates mammalian target of rapamycin complex 1 (mtorc1) kinase by displacing fk506 binding protein 38 (fkbp38) and exerting an allosteric effect. J Biol Chem. 2011;286(34):29568–74.CrossRefPubMedPubMedCentral
54.
Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of tsc2 by erk: implications for tuberous sclerosisand cancer pathogenesis. Cell. 2005;121(2):179–93.CrossRefPubMed
55.
Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, Thibault P, Fingar DC, Roux PP. Erk1/2 phosphorylate raptor to promote ras-dependent activation of mtor complex 1 (mtorc1). J Biol Chem. 2011;286(1):567–77.CrossRefPubMed
56.
You JS, Frey JW, Hornberger TA. Mechanical stimulation induces mtor signaling via an erk-independent mechanism: implications for a direct activation of mtor by phosphatidic acid. PLoS ONE. 2012;7(10):47258.CrossRef
57.
Sanchez AM, Candau RB, Bernardi H. Foxo transcription factors: their roles in the maintenance of skeletal muscle homeostasis. Cell Mol Life Sci. 2014;71(9):1657–71.CrossRefPubMed
58.
Bodine SC, Latres E, Baumhueter S, Lai VK-M, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294(5547):1704–8.CrossRefPubMed
59.
Bodine SC, Baehr LM. Skeletal muscle atrophy and the e3 ubiquitin ligases murf1 and mafbx/atrogin-1. Am J Physiol Endocrinol Metab. 2014;307(6):469–84.CrossRef
60.
Jaafar R, De Larichaudy J, Chanon S, Euthine V, Durand C, Naro F, Bertolino P, Vidal H, Lefai E, N’emoz G. Phospholipase d regulates the size of skeletal muscle cells through the activation of mtor signaling. Cell Commun Signal. 2013;11:1.CrossRef
61.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of akt/pkb by the rictor-mtor complex. Science. 2005;307(5712):1098–101.CrossRefPubMed
62.
Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase bα. Curr Biol. 1997;7(4):261–9.CrossRefPubMed
63.
Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a pkb/akt hydrophobic motif ser-473 kinase as dna-dependent protein kinase. J Biol Chem. 2004;279(39):41189–96.CrossRefPubMed
64.
Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in foxo’s road. Sci STKE. 2003;2003(172):5–5.
65.
Welsh AH, Knight EJ. “magnitude-based inference”: a statistical review. Med Sci Sports Exerc. 2015;47:874–84.CrossRefPubMed
Metadata
Title
Phosphatidic acid: biosynthesis, pharmacokinetics, mechanisms of action and effect on strength and body composition in resistance-trained individuals
Author
Peter Bond
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Nutrition & Metabolism / Issue 1/2017
Electronic ISSN: 1743-7075
DOI
https://doi.org/10.1186/s12986-017-0166-6

Other articles of this Issue 1/2017

Nutrition & Metabolism 1/2017 Go to the issue

Research

Impact of a 6-week non-energy-restricted ketogenic diet on physical fitness, body composition and biochemical parameters in healthy adults

Research

Identification of the principal transcriptional regulators for low-fat and high-fat meal responsive genes in small intestine

Research

Maternal high-fat diet impairs glucose metabolism, β-cell function and proliferation in the second generation of offspring rats

Perspective

Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer

Research

Dynamic and temporal assessment of human dried blood spot MS/MSALL shotgun lipidomics analysis

Research

Lipid overload during gestation and lactation can independently alter lipid homeostasis in offspring and promote metabolic impairment after new challenge to high-fat diet
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits